News
1h
Zacks Investment Research on MSNGSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease DrugGSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston ...
GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...
This marks AbbVie’s second major siRNA deal following its $1.4bn acquisition of Aliada Therapeutics last year.
London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...
The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...
GSK to buy Boston Pharma’s efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD: London, UK Thursday, May 15, 2025, ...
GSK will acquire the liver disease drug efimosfermin from Boston Pharmaceuticals in a deal worth up to $2 billion, The Wall Street Journal reported May 14. The agreement includes a $1.2 billion ...
Aeva Technologies, a firm founded by former Apple engineers that makes sensors used in factories and self-driving vehicles, said it had sold a 6% stake for $50 million to an unnamed strategic partner ...
Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash ...
With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...
British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...
GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results